MAGLE CHEMOSWED HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32 SEK | 0.00% |
|
+5.96% | +26.98% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 185M 17.03M | Sales 2025 * | 216M 19.85M | Capitalization | 346M 31.84M |
|---|---|---|---|---|---|
| Net income 2024 * | 21M 1.93M | Net income 2025 * | 30M 2.76M | EV / Sales 2024 * | 2.16 x |
| Net Debt 2024 * | 53M 4.88M | Net Debt 2025 * | 42M 3.87M | EV / Sales 2025 * | 1.8 x |
| P/E ratio 2024 * |
16.8
x | P/E ratio 2025 * |
11
x | Employees | 78 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 21.39% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +5.96% | ||
| Current month | +5.96% | ||
| 1 month | -5.33% | ||
| 3 months | +28.00% | ||
| 6 months | +40.35% | ||
| Current year | +26.98% |
1 week
30.00
32.00
1 month
30.0034.00
Current year
24.4035.00
1 year
21.4038.00
3 years
20.0042.00
5 years
19.6049.00
10 years
19.6049.00
| Managers | Title | Age | Since |
|---|---|---|---|
Justin Pierce
CEO | Chief Executive Officer | 51 | 14-12-31 |
Petra Sjölin
DFI | Director of Finance/CFO | - | 20-06-30 |
| Chief Operating Officer | 48 | 98-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 15-12-31 | |
| Director/Board Member | 79 | 15-12-31 | |
| Director/Board Member | 44 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 32 | 0.00% | 200 |
| 24-05-06 | 32 | 0.00% | 213 |
| 24-05-03 | 32 | +5.96% | 1,632 |
| 24-05-02 | 30.2 | 0.00% | 32 |
| 24-04-30 | 30.2 | +0.67% | 690 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 05:54 am EDT
More quotes
Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
Sector
Pharmaceuticals
Calendar
2024-07-17
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.98% | 31.7M | |
| +32.35% | 698B | |
| +26.51% | 568B | |
| -4.64% | 358B | |
| +19.02% | 328B | |
| +3.62% | 283B | |
| +16.34% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +7.93% | 165B |
- Stock Market
- Equities
- MAGLE Stock